Abstract
The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial infarction (AMI) does not decrease regardless of implementation of new technologies supporting opening culprit coronary artery and solving of ischemia-relating stenosis with primary percutaneous coronary intervention (PCI). Numerous studies have examined the diagnostic and prognostic potencies of circulating cardiac biomarkers in acute coronary syndrome / AMI and HF after AMI, and even fewer have been depicted the utility of biomarkers in AMI patients undergoing primary PCI. The aim of the review is focused an attention on non-coding cell-free and exosomal micro RNA as biomarkers of HF. Although there is a large number of evidence regarding predicative value of signature of miRNA in adverse cardiac remodelling and HF with different phenotypes, large clinical trials are required to be performed in the future to clearly elucidate whether miRNAs could be suitably for personalizing HF therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
